WO2016184103A1 - 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用 - Google Patents

一种胆酸改性氨基葡萄糖衍生物及制备方法和应用 Download PDF

Info

Publication number
WO2016184103A1
WO2016184103A1 PCT/CN2015/098527 CN2015098527W WO2016184103A1 WO 2016184103 A1 WO2016184103 A1 WO 2016184103A1 CN 2015098527 W CN2015098527 W CN 2015098527W WO 2016184103 A1 WO2016184103 A1 WO 2016184103A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholic acid
glucosamine
derivative
active ester
acid
Prior art date
Application number
PCT/CN2015/098527
Other languages
English (en)
French (fr)
Inventor
任力
侯思润
刘卅
姚航
薛婧晨
王迎军
王琳
Original Assignee
华南理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华南理工大学 filed Critical 华南理工大学
Publication of WO2016184103A1 publication Critical patent/WO2016184103A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a cholic acid modified glucosamine derivative and a process for the preparation thereof.
  • the cholic acid-modified glucosamine derivative of the present invention can be used for treating an osteoarthritis drug, an organic matrix of a cartilage repairing material, and can be used for constructing an in situ shaped modified glucosamine functionalized hydrogel cartilage repairing material.
  • D-glucosamine As the final degradation product of chitin, D-glucosamine has the treatment of arthritis, anti-inflammatory, stimulating proteoglycan synthesis, immunomodulation, and participate in the construction of human tissues and cell membranes. It is an intermediate substance for the synthesis of proteoglycan macromolecules. Due to their physiological activity, such compounds are widely used in medicine and biology, and research in related fields is receiving more and more attention.
  • Cholic acid is derived from an amphiphilic substance with special biological activity and good biocompatibility in humans and animals. Its molecular anthracene has carboxyl groups and hydroxyl groups, which are easy to be chemically modified. Therefore, it is easy to carry out glucosamine with bile acid.
  • the chemical modification can prepare a derivative having no polymerizable group as a drug for treating osteoarthritis; or further preparing a derivative having a polymerizable functional group as a biologically active biomedical material application.
  • Existing cartilage repair materials have many problems to be solved, such as biological activity, biocompatibility, safety and non-toxicity of degradation products, mechanical strength of materials, and implant rejection.
  • glucosamine derivatives In the synthesis of glucosamine derivatives, the literature has been reported. According to different functional groups, it is classified into N-position derivatives (acylated derivatives, alkylated derivatives, amino acid derivatives, etc.), O-position derivatives (carboxylic acid derivatives, phospholipid derivatives, olefin derivatives, Aromatic derivatives, etc.) and metal complexes.
  • N-position derivatives acylated derivatives, alkylated derivatives, amino acid derivatives, etc.
  • O-position derivatives carboxylic acid derivatives, phospholipid derivatives, olefin derivatives, Aromatic derivatives, etc.
  • metal complexes metal complexes.
  • the invention proposes a method for modifying glucosamine by using bile acid, and solves the problems existing in the prior art for treating osteoarthritis and cartilage repairing materials.
  • a cholic acid modified glucosamine derivative having the specific structure of formula (I):
  • R 1 is H or OH
  • R 2 is H or OH
  • the preparation method of the above cholic acid modified glucosamine derivative comprises the following steps:
  • the active ester of cholic acid is prepared by reacting cholic acid with excess N-hydroxysuccinimide or 1-hydroxybenzotriazole in the presence of carbodiimide as a catalyst and tetrahydrofuran as a solvent system;
  • the active ester of cholic acid and D-glucosamine are reacted under the condition of a tertiary organic amine as a catalyst for 6-12 hours to obtain a derivative having no polymerizable group; or at -20 ° C to -15 ° C
  • the cholic acid active ester is first reacted with the vinyl group-containing acid chloride for 110-130 minutes, then returned to room temperature for reaction overnight, and further reacted with D-glucosamine under the condition of an organic tertiary amine as a catalyst at room temperature for 6-12 hours.
  • a derivative having a polymerizable group is obtained.
  • the carbodiimide is N,N'-dicyclohexylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N,N'- One or more of diisopropylcarbodiimide.
  • the D-glucosamine is D-glucosamine hydrochloride.
  • the vinyl-containing acid chloride is acryloyl chloride or methacryloyl chloride.
  • the organic tertiary amine is N,N-diisopropylethylamine or triethylamine.
  • N-hydroxysuccinimide or 1-hydroxybenzotriazole is in excess, and the ratio of the amount of cholic acid to N-hydroxysuccinimide or 1-hydroxybenzotriazole is 1:1. 1:1.5.
  • the carbodiimide is in excess, and the ratio of the amount of the bile acid to the carbodiimide is 1:1.5 to 1:2.
  • the organic tertiary amine is in excess, the ratio of the amount of the active ester of the cholic acid to the organic tertiary amine is 1:1 to 1:1.5; the acid chloride containing the vinyl is in excess, the active ester of the bile acid and the vinyl group The ratio of the amount of the acid chloride is 1:2 to 1:2.5; the D-glucosamine is in excess, and the ratio of the amount of the active ester of cholic acid to the substance of D-glucosamine is 1:1 to 1:1.5.
  • the present invention has the following advantages:
  • the preparation of the above-mentioned cholic acid-modified glucosamine derivative according to the present invention has a road The line is short, easy to operate, easy to purify, and high in yield.
  • the polymerizable group-free derivative prepared by the present invention can be used as a drug for treating osteoarthritis.
  • the polymerizable group-derived derivative prepared by the invention has unique biological activity, good biocompatibility, can be used for an organic matrix of a cartilage repairing material, and can be used for constructing an in situ shaped modified glucosamine. Functionalized hydrogel cartilage repair material.
  • Example 2 is a nuclear magnetic resonance spectrum of a non-polymerizable group-containing cholic acid-modified glucosamine derivative prepared in Example 1;
  • Example 3 is a graph showing the results of cell proliferation toxicity test of the non-polymerizable group-containing cholic acid-modified glucosamine derivative prepared in Example 1;
  • Figure 4 is a graph showing the cell life-lived staining of the non-polymerizable group-containing cholic acid-modified glucosamine derivative prepared in Example 1;
  • Figure 5 is a structural formula of a cholic acid-modified glucosamine derivative having a polymerizable group prepared in Example 3;
  • Figure 6 is a nuclear magnetic resonance spectrum of a cholic acid-modified glucosamine derivative having a polymerizable group prepared in Example 3.
  • Figure 7 is a graph showing the results of cell proliferation toxicity test of the non-polymerizable group-containing cholic acid-modified glucosamine derivative prepared in Example 3;
  • Example 8 is a non-polymerizable group-containing cholic acid-modified glucosamine derivative prepared in Example 1. Biological cell death and death staining map;
  • Figure 9 is a structural formula of a cholic acid-modified glucosamine derivative having a polymerizable group prepared in Example 4.
  • Example 3 is a bile acid-modified glucosamine derivative synthesized in Example 1 dissolved in a medium to promote cell proliferation (L929 mouse fibroblast cell line, the cell line is GB/T16886.5-2003 in vitro cytotoxicity) The effect of the experiment specified cells).
  • the control group was a normal medium, and the results showed that slight cytotoxicity occurred when the concentration reached a concentration of 1 mM, and 1.5 mM showed significant toxicity, indicating that the modified amino sugar was safe to cells below 1 mM.
  • Fig. 4 is a graph showing the results of staining of dead and viable cells of cell culture (L929 cells) in different concentrations of the synthesized cholic acid-modified glucosamine derivative (the scale is 50 ⁇ m), and the results are basically the same as the quantitative results, and the cells are changed at 1 mM.
  • the aminoglycan concentration medium can still survive in large quantities.
  • a derivative having a polymerizable group is prepared: an acryloyl cholic acid modified glucosamine derivative, comprising the steps of:
  • Figure 7 is a third embodiment of the synthesis of cholic acid modified glucosamine derivative cell culture medium extract (there is no insoluble medium with the modified amino sugar, according to the national standard GB/T 16886.5-2003 in vitro cytotoxicity test extract standard
  • Fig. 8 is a picture showing the staining of dead cells of cells in the cell culture medium of the bile acid-modified glucosamine derivative of Example 3 (the scale is 50 ⁇ m), and the results are consistent with the quantitative results, and the modified ammonia sugar has different concentrations of dip. The extract does not affect the survival of the cells.
  • Example 4
  • Example 4 The structural formula of the synthetic cholic acid modified glucosamine derivative is shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明涉及一种胆酸改性氨基葡萄糖衍生物及制备方法和应用，所述衍生物如式(I)所示，其中，R1为H或OH，R2为H或OH，R3为H、CH2＝CHCO-或CH2＝C(CH3)CO-。在碳二酰亚胺缩合试剂的存在下，胆酸与过量N-羟基琥珀酰亚胺或1-羟基苯并三唑反应，生成胆酸活性酯，进而与D-氨基葡萄糖反应，得到无可聚合基团的衍生物；或胆酸活性酯先与含乙烯基的酰氯反应，进而与D-氨基葡萄糖反应，得到有可聚合基团的衍生物。本发明衍生物具有良好的生物相容性，无可聚合基团的衍生物可作为治疗骨关节炎的药物，有可聚合基团的衍生物用于软骨修复材料的有机基质，或用于构建原位成型氨基葡萄糖功能化水凝胶。

Description

一种胆酸改性氨基葡萄糖衍生物及制备方法和应用 技术领域
本发明涉及胆酸改性氨基葡萄糖衍生物及其制备方法。本发明中的胆酸改性氨基葡萄糖衍生物可用于治疗骨关节炎的药物、软骨修复材料的有机基质，并可用于构建原位成型改性氨基葡萄糖功能化水凝胶软骨修复材料。
背景技术
D-氨基葡萄糖作为甲壳素的最终降解产物，具有治疗关节炎、消炎、刺激蛋白多糖的合成，免疫调节作用，并参与构造人体组织和细胞膜，是蛋白多糖大分子合成的中间物质。由于此类化合物具有生理活性，因此在医药、生物领域应用较为广泛，相关领域的研究也越来越受重视。胆酸来源于人和动物体内的具有特殊生物活性和良好生物相容性的两亲性物质，其分子的甾环上有羧基和羟基，易于进行化学修饰，因此，用胆酸对氨基葡萄糖进行化学改性可以制备无可聚合基团的衍生物，作为治疗骨关节炎的药物；或进一步制备有可聚合功能基团的衍生物，作为具有生物活性的生物医用材料应用。现有的软骨修复材料存在诸多亟待解决的问题，如生物活性、生物相容性、降解产物是否安全无毒、材料力学强度，植入排斥反应等。
在氨基葡萄糖衍生物的合成方面，文献已有报导。根据官能团的不同，分为N-位衍生物(酰化衍生物、烷基化衍生物、氨基酸衍生物等)，O-位衍生物(羧酸化衍生物、磷脂化衍生物、烯烃衍生物、 芳香衍生物等)以及金属配合物等。而用甾体类化合物对氨基葡萄糖的改性报道较少，目前还没有关于具有可聚合功能基团的胆酸改性氨基葡萄糖的单体报道。
发明内容
本发明提出采用胆酸改性氨基葡萄糖的方法，解决现有治疗骨关节炎的药物，以及软骨修复材料所存在的问题。
本发明的目的通过以下技术方案实现：
一种胆酸改性氨基葡萄糖衍生物，具体结构如式(I)：
Figure PCTCN2015098527-appb-000001
其中，R1为H或OH，R2为H或OH，R3为H、CH2＝CHCO-或CH2＝C(CH3)CO-。
上述胆酸改性氨基葡萄糖衍生物的制备方法，包括下述步骤：
1)由胆酸与过量N-羟基琥珀酰亚胺或1-羟基苯并三唑，在碳二酰亚胺作催化剂，四氢呋喃为溶剂体系条件下反应制得胆酸活性酯；
2)室温下，胆酸活性酯与D-氨基葡萄糖在有机叔胺作催化剂的条件下反应6-12小时，制得无可聚合基团的衍生物；或在-20℃到-15℃ 下，胆酸活性酯先与含乙烯基的酰氯反应110-130分钟后，回复到室温反应过夜，进而在室温下，与D-氨基葡萄糖在有机叔胺作催化剂的条件下反应6-12小时，制得有可聚合基团的衍生物。
所述的碳二酰亚胺是N,N'-二环己基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐和N,N'-二异丙基碳二亚胺中的一种或两种以上。
所述的D-氨基葡萄糖是D-氨基葡萄糖盐酸盐。
所述的含乙烯基的酰氯是丙烯酰氯或甲基丙烯酰氯。
所述的有机叔胺是N，N-二异丙基乙胺或三乙胺。
所述N-羟基琥珀酰亚胺或1-羟基苯并三唑是过量的，胆酸与N-羟基琥珀酰亚胺或1-羟基苯并三唑的物质的量之比为1:1～1:1.5。
所述碳二酰亚胺是过量的，胆酸与碳二酰亚胺的物质的量之比为1:1.5～1:2。
所述有机叔胺是过量的，胆酸活性酯与有机叔胺的物质的量之比为1:1～1:1.5；含乙烯基的酰氯是过量的，胆酸活性酯与含乙烯基的酰氯的物质的量之比为1:2～1:2.5；D-氨基葡萄糖是过量的，胆酸活性酯与D-氨基葡萄糖的物质的量之比为1:1～1:1.5。
上述制得的胆酸改性氨基葡萄糖衍生物在制备治疗骨关节炎的药物中的应用，或在软骨修复材料中的应用，或在构建原位成型的氨基葡萄糖功能化水凝胶中的应用。
与现有技术相比，本发明具有如下优点：
(1)本发明所述的制备上述胆酸改性氨基葡萄糖衍生物具有路 线简短，操作方便，提纯容易，收率较高等优点。
(2)本发明所制备的无可聚合基团的衍生物，可用于作为治疗骨关节炎的药物。
(3)本发明所制备的有可聚合基团的衍生物，具有独特的生物活性，良好的生物相容性，可用于软骨修复材料的有机基质，并可用于构建原位成型改性氨基葡萄糖功能化水凝胶软骨修复材料。
附图说明
图1为实施例1、2制备的无可聚合基团的胆酸改性氨基葡萄糖衍生物的结构式；
图2为实施例1制备的无可聚合基团的胆酸改性氨基葡萄糖衍生物的核磁共振氢谱；
图3为实施例1制备的无可聚合基团的胆酸改性氨基葡萄糖衍生物的细胞增殖毒性实验结果图；
图4为实施例1制备的无可聚合基团的胆酸改性氨基葡萄糖衍生物的细胞死活染色图；
图5为实施例3制备的有可聚合基团的胆酸改性氨基葡萄糖衍生物的结构式；
图6为实施例3制备的有可聚合基团的胆酸改性氨基葡萄糖衍生物的核磁共振氢谱。
图7为实施例3制备的无可聚合基团的胆酸改性氨基葡萄糖衍生物的细胞增殖毒性实验结果图；
图8为实施例1制备的无可聚合基团的胆酸改性氨基葡萄糖衍 生物的细胞死活染色图；
图9为实施例4制备的有可聚合基团的胆酸改性氨基葡萄糖衍生物的结构式。
具体实施方式
下面结合具体实施例对本发明作进一步具体详细描述，但本发明的实施方式不限于此，对于未特别注明的工艺参数，可参照常规技术进行。
实施例1
制备无可聚合基团的衍生物：胆酸改性氨基葡萄糖衍生物，包括如下步骤：
4.0858g(0.01mol)胆酸，1.1509g(0.01mol)N-羟基琥珀酰亚胺加入150ml三颈瓶，搅拌溶解于30ml四氢呋喃，在0℃下，缓慢滴加含3.0949g(0.015mol)N,N'-二环己基碳二亚胺的10ml四氢呋喃溶液，保温2h后，回到室温，继续反应18h后停止反应，抽滤取滤液，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为石油醚/乙酸乙酯(1/4)，得胆酸活性酯A4.258g，产率为84.21％。
2.1563g(0.01mol)的氨基葡萄糖加入100ml单颈瓶中，加入30ml的N,N-二甲基甲酰胺/去离子水(2/1)，再滴入1.0119g(0.01mol)的三乙胺，搅拌10min，后加入5.057g(0.01mol)的胆酸活性酯A，反应6h后停止反应，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(8/1)，得到产物4.134g，产率为72.65％。
上述合成的胆酸改性氨基葡萄糖衍生物的结构式如图1所示。
如图2所示1H-NMR(DMSO-d6,400MHz)分析证实:0.57(s,3H), 0.80(s,3H),0.92(d,3H),1.20～2.25(m,24H),3.15～4.90(m,16H),6.35(d,1H),7.48(d,1H).
图3为实施例1合成的的胆酸改性氨基葡萄糖衍生物不同浓度溶于培养基对细胞增殖(L929小鼠成纤维细胞系，该细胞系为国标GB/T16886.5-2003体外细胞毒性实验指定细胞)的影响情况。控制组为正常培养基，结果表明当浓度达到1mM浓度时才出现轻微细胞毒性，1.5mM出现明显毒性，说明该改性氨糖在1mM以下对细胞安全。
图4为合成的的胆酸改性氨基葡萄糖衍生物不同浓度溶于培养基对细胞存活(L929细胞)的死活细胞染色结果图(标尺为50μm)，结果与定量结果基本一致，细胞在1mM改性氨糖浓度培养基中仍然能大量存活。
实施例2
制备无可聚合基团的衍生物：胆酸改性氨基葡萄糖衍生物，包括如下步骤：
4.0858g(0.01mol)胆酸，2.0269g(0.015mol)1-羟基苯并三唑加入150ml三颈瓶，搅拌溶解于30ml四氢呋喃，在0℃下，缓慢滴加含3.8340g(0.02mol)的1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐的10ml四氢呋喃溶液，保温2h后，回到室温，继续反应24h后停止反应，抽滤取滤液，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为石油醚/乙酸乙酯(1/4)，得胆酸活性酯B3.833g，产率为75.79％。
3.23445g(0.015mol)的氨基葡萄糖加入100ml单颈瓶中，加入30ml的N,N-二甲基甲酰胺/去离子水(2/1)，再滴入1.9386g(0.015mol) 的N,N-二异丙基乙胺，搅拌10min，后加入5.2571g(0.01mol)的胆酸活性酯B，反应12h后停止反应，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(8/1)，得到产物4.134g，产率为72.65％。合成产物结构式如图1所示。
实施例3
制备有可聚合基团的衍生物：丙烯酰胆酸改性氨基葡萄糖衍生物，包括如下步骤：
4.0858g(0.01mol)胆酸，1.1509g(0.01mol)N-羟基琥珀酰亚胺加入150ml三颈瓶，搅拌溶解于30ml四氢呋喃，在0℃下，缓慢滴加含1.8915g(0.015mol)N,N'-二异丙基碳二亚胺的10ml四氢呋喃溶液，保温2h后，回到室温，继续反应18h后停止反应，抽滤取滤液，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为石油醚/乙酸乙酯(1/4)，得胆酸活性酯A，质量4.258g，产率为84.21％。
2.5283g(0.005mol)的胆酸活性酯A，1.012g(0.01mol)的三乙胺(除水)加入100ml单颈瓶中，在0℃下，加入30ml的四氢呋喃(除水)，干冰冷却到-15℃，滴入0.905g(0.01mol)丙烯酰氯，保温两小时后回复到室温，继续反应过夜，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(100/1)。得到丙烯酰胆酸活性酯A，质量0.8221g，产率29.38％。
2.1563g(0.01mol)的氨基葡萄糖加入100ml单颈瓶中，加入30ml的dmf/H2O(2/1)，再滴入1.0119g(0.01mol)三乙胺，搅拌10min，后加入5.597g(0.01mol)的丙烯酰胆酸活性酯A，反应6h后停止反应， 旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(8/1)。得到产物3.803g，产率61.04％。
实施例3合成的胆酸改性氨基葡萄糖衍生物的结构式如图5所示。
如图6所示，1H-NMR(DMSO-d6,400MHz)分析证实:0.58(s,3H),0.84(s,3H),0.92(d,3H),0.96～2.46(m,24H),3.03～4.90(m,15H),5.88(d,J＝10Hz,1H),6.12(dd,J1,2＝10Hz,17.2Hz,1H),6.28(d,J＝17.2Hz,1H),6.35(d,1H),7.48(d,1H).
图7为实施例3合成胆酸改性氨基葡萄糖衍生物细胞培养基浸提液(有与该改性氨糖不溶于培养基，按照国标GB/T 16886.5-2003体外细胞毒性实验浸提液标准制备浸提液)对细胞(L929)增殖毒性影响结果，使用不同浸提液浓度为参比(饱和浸提液为1倍)，控制组为正常培养基所有浸提液浓度均不会对细胞的增殖毒性发生影响。
图8为实施例3合成胆酸改性氨基葡萄糖衍生物细胞培养基浸提液对细胞存活的死活细胞染色图片(标尺为50μm)，结果与定量结果一致，该改性氨糖不同浓度的浸提液不会对细胞的存活发生影响。实施例4
制备有可聚合基团的衍生物：甲基丙烯酰胆酸改性氨基葡萄糖衍生物，包括以下步骤：
4.0858g(0.01mol)胆酸，2.0269g(0.015mol)1-羟基苯并三唑加入150ml三颈瓶，搅拌溶解于30ml四氢呋喃，在0℃下，缓慢滴加含3.8340g(0.02mol)的1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐的10ml四氢呋喃溶液，保温2h后，回到室温，继续反应24h后停止反 应，抽滤取滤液，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为石油醚/乙酸乙酯(1/4)，得胆酸活性酯B，质量3.833g，产率为75.79％。
2.6286g(0.005mol)的胆酸活性酯B，1.012g(0.01mol)的三乙胺(除水)加入100ml单颈瓶中，在0℃下，加入30ml的四氢呋喃(除水)，干冰冷却到-20℃，滴入1.0453(0.01mol)甲基丙烯酰氯，保温两小时后回复到室温，继续反应过夜，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(100/1)。得到甲基丙烯酰胆酸活性酯0.812g，产率27.38％
2.1563g(0.01mol)的GA加入100ml单颈瓶中，加入30ml的dmf/H2O(2/1)，再滴入1.0119g(0.01mol)三乙胺，搅拌10min，后加入5.9374g(0.01mol)的甲基丙烯酰胆酸活性酯，反应12h后停止反应，旋转蒸发除去溶剂。用硅胶柱层析提纯，洗脱剂为二氯甲烷/甲醇(8/1)。得到产物3.8519g，产率60.47％。
实施例4合成胆酸改性氨基葡萄糖衍生物结构式如图9所示。

Claims (10)

  1. 一种胆酸改性氨基葡萄糖衍生物，其特征在于，具体结构如式(I)：
    Figure PCTCN2015098527-appb-100001
    其中，R1为H或OH，R2为H或OH，R3为H、CH2＝CHCO-或CH2＝C(CH3)CO-。
  2. 权利要求1所述的胆酸改性氨基葡萄糖衍生物的制备方法，其特征在于，包括下述步骤：
    1)由胆酸与过量N-羟基琥珀酰亚胺或1-羟基苯并三唑，在碳二酰亚胺作催化剂，四氢呋喃为溶剂的条件下反应制得胆酸活性酯；
    2)室温下，胆酸活性酯与D-氨基葡萄糖在有机叔胺作催化剂的条件下反应6-12小时，制得无可聚合基团的衍生物；或在-20℃到-15℃下，胆酸活性酯先与含乙烯基的酰氯反应110-130分钟后，回复到室温反应过夜，进而在室温下，与D-氨基葡萄糖在有机叔胺作催化剂的条件下反应6-12小时，制得有可聚合基团的衍生物。
  3. 根据权利要求2所述的制备方法，其特征在于，所述的碳二酰亚胺是N,N'-二环己基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳二亚 胺盐酸盐和N,N'-二异丙基碳二亚胺中的一种或两种以上。
  4. 根据权利要求2所述的制备方法，其特征在于，所述的D-氨基葡萄糖是D-氨基葡萄糖盐酸盐。
  5. 根据权利要求2所述的制备方法，其特征在于，所述的含乙烯基的酰氯是丙烯酰氯或甲基丙烯酰氯。
  6. 根据权利要求2所述的制备方法，其特征在于，所述的有机叔胺是N，N-二异丙基乙胺或三乙胺。
  7. 根据权利要求2～6任一项所述的制备方法，其特征在于，所述胆酸与N-羟基琥珀酰亚胺或1-羟基苯并三唑的物质的量之比为1:1～1:1.5。
  8. 根据权利要求2～6任一项所述的制备方法，其特征在于，所述胆酸与碳二酰亚胺的物质的量之比为1:1.5～1:2。
  9. 根据权利要求2～6任一项所述的制备方法，其特征在于，所述胆酸活性酯与有机叔胺的物质的量之比为1:1～1:1.5；胆酸活性酯与含乙烯基的酰氯的物质的量之比为1:2～1:2.5；胆酸活性酯与D-氨基葡萄糖的物质的量之比为1:1～1:1.5。
  10. 权利要求1所述的胆酸改性氨基葡萄糖衍生物在制备治疗骨关节炎的药物中的应用，或在软骨修复材料中的应用，或在构建原位成型的氨基葡萄糖功能化水凝胶中的应用。
PCT/CN2015/098527 2015-05-18 2015-12-23 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用 WO2016184103A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510253403.1A CN104961789A (zh) 2015-05-18 2015-05-18 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用
CN201510253403.1 2015-05-18

Publications (1)

Publication Number Publication Date
WO2016184103A1 true WO2016184103A1 (zh) 2016-11-24

Family

ID=54215908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/098527 WO2016184103A1 (zh) 2015-05-18 2015-12-23 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用

Country Status (2)

Country Link
CN (1) CN104961789A (zh)
WO (1) WO2016184103A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961789A (zh) * 2015-05-18 2015-10-07 华南理工大学 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用
CN108504342A (zh) * 2018-04-09 2018-09-07 王建东 一种堵水剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781352A (zh) * 2009-12-17 2010-07-21 上海吉友医药科技有限公司 20-o-糖基及其原人参二醇类化合物及其制备方法
CN102225962A (zh) * 2011-04-21 2011-10-26 东北林业大学 小檗碱9位酰胺键合胆酸的新衍生物及制备方法
CN104961789A (zh) * 2015-05-18 2015-10-07 华南理工大学 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301037B6 (cs) * 2007-09-06 2009-10-21 Vysoká škola chemicko-technologická v Praze Amidové konjugáty steroidních a žlucových kyselin s D-glukosaminem a zpusob jejich prípravy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781352A (zh) * 2009-12-17 2010-07-21 上海吉友医药科技有限公司 20-o-糖基及其原人参二醇类化合物及其制备方法
CN102225962A (zh) * 2011-04-21 2011-10-26 东北林业大学 小檗碱9位酰胺键合胆酸的新衍生物及制备方法
CN104961789A (zh) * 2015-05-18 2015-10-07 华南理工大学 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUKH, M. ET AL.: "Metal Coordination as a Tool for Controlling the Self-Assembling and Gelation Properties of Novel Type Cholic Amide-Phenanthroline Gelating Agent", TETRAHEDRON, vol. 59, no. 23, 31 December 2003 (2003-12-31), pages 4069 - 4076, XP004427965 *
NOVAKOVA, Z. ET AL.: "Steroid and Bile Acids Amide Conjugates with D-Glucosamine", COLLECT. CZECH . CHEM. COMMUN., vol. 76, no. 1, 5 January 2011 (2011-01-05), pages 65 - 74, XP055330800, ISSN: 0010-0765 *
NOVAKOVA, Z. ET AL.: "Steroid and Bile Acids Amide Conjugates with D-Glucosamine", COLLECT. CZECH . CHEM.COMMUN., vol. 76, no. 1, 5 January 2011 (2011-01-05), pages 65 - 74, XP055330800, ISSN: 0010-0765 *
PIERRE, T. ET AL.: "Molecular Hydrogels from Bile Acid Analogues with Neutral Side Chains: Network Architectures and Viscoelastic Properties. Junction Zones, Spherulites, and Crystallites: Phenomenological Aspects of the Gel Metastability", J. PHYS. CHEM. B, vol. 110, no. 31, 19 July 2006 (2006-07-19), pages 15224 - 15233, XP055330870 *

Also Published As

Publication number Publication date
CN104961789A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
US10842753B2 (en) Modified alginates for cell encapsulation and cell therapy
RU2598552C2 (ru) Сложные эфиры гиалуроновой кислоты, их получение и применение в дерматологии
US20150291706A1 (en) Photoreactive Derivative of Hyaluronic Acid, Method of Preparation Thereof, 3D.Crosslinked Derivative of Hyaluronic Acid, Method of Preparation and Use Thereof
CN105601549A (zh) 刺激敏感型二异氰酸酯
WO2019227525A1 (zh) 一种壳寡糖基化合物的应用及其制备方法
WO2016184103A1 (zh) 一种胆酸改性氨基葡萄糖衍生物及制备方法和应用
JP2021500436A (ja) 炎症症状の治療における官能化ヒアルロン酸またはその誘導体
CN107903339B (zh) 一种含两性氨基酸基团的壳聚糖衍生物及制备方法与应用
CN101870719B (zh) 一种同时具有二硫化学键和甾体骨架结构的有机功能化合物、制备方法和用途
CN101864046B (zh) 氨基葡萄糖改性聚乙二醇双丙烯酸酯水凝胶及其制备方法与应用
CN102321140A (zh) 一种由天然胆固醇和氨基酸合成的类脂质阳离子功能分子、制备方法及其用途
CN115260053A (zh) 一种具有抗肿瘤活性的化合物及其制备方法与它的用途
CN109988297B (zh) 一种烷基化聚乙二醇化奥沙利铂前体的制备方法
CN112679409A (zh) 一种4-吲哚-取代硫半脲衍生物及其制备方法和应用
CN114933554B (zh) 一种基于异斯特维醇的可注射型超分子水凝胶及其制备方法与应用
CN103214541A (zh) 含有天然胆固醇和赖氨酸类脂质阳离子有机功能分子及其脂质体、制备方法和应用
CN114835769B (zh) 20-酰胺-(异羟肟酸)-孕烯醇酮类缀合物及其制备方法
EP2963020B1 (en) Novel compound, production method therefor, and use of said compound
CN111606828B (zh) (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途
Das et al. One-pot synthesis of chitosan–dehydropregnenolone acetate ketimine nanoparticles and their antifungal bioevaluation
EP3147300B1 (en) N-acetylglucosamine sugar chain group-containing polymer, carrier compound for drug delivery, drug preparation, and drug delivery system
Yu Automated Glycan Assembly to Study Carbohydrate Materials
CN116688144A (zh) 一种光触发no供体型生物可降解聚合物纳米凝胶的制备方法和应用
CN115010669A (zh) 一种核糖核酸酶靶向嵌合物工具及其制备方法和应用
KR20030068090A (ko) 스핑고지질류를 이용한 비타민씨 유도체 및 그것의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15892477

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 16/05/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 15892477

Country of ref document: EP

Kind code of ref document: A1